Bacterial Infection Due To Klebsiella Pneumoniae — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for bacterial infection due to klebsiella pneumoniae. 6 active patents protecting 2 drugs from 2+ originators. First major cliff: 2030. Daily refresh.

2
Approved drugs
6
Active US patents
67/100
Avg vulnerability
—
Annual revenue covered

Originators in Bacterial Infection Due To Klebsiella Pneumoniae

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AbbVie 4 patents Novartis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating bacterial infection due to klebsiella pneumoniae. Each bar = one year. Y-axis scaled to peak year (3 patents).

1
28
3
30
2
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Teflaro
CEFTAROLINE FOSAMIL
 AbbVie 4 61 — 2030-09-21
Tobi
tobramycin
 Novartis 2 72 — 2028-09-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8869794 Tobi method of use 75 2028-09-12
8247400 Teflaro method of use 73 2031-02-10
8247400 Teflaro method of use 73 2031-02-10
10207066 Tobi method of use 68 2030-11-04
9629861 Teflaro formulation 48 2030-09-21
9629861 Teflaro formulation 48 2030-09-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9629861 Teflaro formulation 48 2030-09-21
9629861 Teflaro formulation 48 2030-09-21
10207066 Tobi method of use 68 2030-11-04
8247400 Teflaro method of use 73 2031-02-10
8247400 Teflaro method of use 73 2031-02-10
8869794 Tobi method of use 75 2028-09-12

Related